ApoB Goal Cost-Effective in Primary Prevention
Strategy increased quality-adjusted life-years and showed favorable cost-effectiveness vs low-density lipoprotein cholesterol and non–high-density lipoprotein cholesterol goals
-
By
-
Kathryn Wighton
-
April 15, 2026
-
-
1
ApoB-targeted lipid therapy produced 1,324 additional quality-adjusted life-years compared to non-HDL-C strategies in primary prevention.
-
2
The incremental cost-effectiveness ratio for apoB-guided therapy was $30,300 per quality-adjusted life-year gained.
-
3
ApoB-guided treatment intensified in 64% of patients, outperforming non-HDL-C and LDL-C targets at 57% and 51%, respectively.
-
4
In sex-specific analyses, apoB strategies yielded cost-effectiveness ratios of $35,900 for women and $26,600 for men.
-
5
Findings suggest that apoB may be a superior target for treatment intensification in primary prevention of ASCVD.
